In the context of acute myeloid leukemia (AML), the loss of CDC42 disrupts cell polarity and division asymmetry, leading to the alteration of leukemia-initiating cell fate in differentiation therapy [25]. This evidence concerns the gene CDC42 and acute myeloid leukemia.